Matthew J. LaMarche

Sanofi (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.9kcitations156works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(57), Galectins and Cancer Biology(16), Melanoma and MAPK Pathways(14), Cancer Treatment and Pharmacology(14), Bioactive Compounds and Antitumor Agents(12)

Publications156 total

The Logic of Chemical Optimization
Journal of Medicinal Chemistry·2025· 2 cited
Relationships between charcoal property and post fire productivity in the boreal forest
Forest Ecosystems·2024· 1 citedOpen Access
Predictions of Colloidal Molecular Aggregation Using AI/ML Models
ACS Omega·2024· 5 citedOpen Access
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Journal of Medicinal Chemistry·2024· 12 citedOpen Access
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Data from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Morvarid Mohseni(13), Michael Acker(11), Travis Stams(11), Jennifer A. Leeds(11), Michelle Fodor(10), Amos B. Smith(9), Mitsunori Kato(8), Michael A. Patane(8), Zhouliang Chen(7), Elin M. Rann(7), Stacey Tiamfook(7), Brant Firestone(6), Shumei Liu(6), Michael D. Shultz(6), Jonathan R. LaRochelle(6), Stephen C. Blacklow(6), Joanne Dzink-Fox(6), Matthew J. Meyer(5), Minying Pu(5), Timothy M. Ramsey(5)